{"id":"ssgj-707","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL3697373","moleculeType":"Small molecule","molecularWeight":"427.46"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SSGJ-707 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing the immune response against cancer cells.","oneSentence":"SSGJ-707 is a small molecule that targets the PD-1/PD-L1 pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:03.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07489066","phase":"PHASE2","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-01","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)","enrollment":120},{"nctId":"NCT07476287","phase":"PHASE2","title":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-05-15","conditions":"Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT07227415","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-10","conditions":"Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer","enrollment":224},{"nctId":"NCT07227298","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-01-30","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer","enrollment":162},{"nctId":"NCT07421700","phase":"PHASE1, PHASE2","title":"A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-27","conditions":"Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma","enrollment":132},{"nctId":"NCT07392892","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-03-02","conditions":"Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":840},{"nctId":"NCT06980272","phase":"PHASE3","title":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-06-20","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":420},{"nctId":"NCT06522828","phase":"PHASE2","title":"A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","status":"RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-10-10","conditions":"Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer","enrollment":80},{"nctId":"NCT06493760","phase":"PHASE2","title":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-09-03","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT06412471","phase":"PHASE2","title":"A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients","status":"RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-07-26","conditions":"First-line Advanced NSCLC Patients","enrollment":235},{"nctId":"NCT06361927","phase":"PHASE2","title":"A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients","status":"RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-05-15","conditions":"NSCLC","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SSGJ-707","genericName":"SSGJ-707","companyName":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","companyId":"sunshine-guojian-pharmaceutical-shanghai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SSGJ-707 is a small molecule that targets the PD-1/PD-L1 pathway. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}